FDA Gives OK to Polivy plus Rituxan-Bendamustine Combo to Treat Advanced DLBCL
News
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq), used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed or ... Read more